A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2016
At a glance
- Drugs Brontictuzumab (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; First in man
- Sponsors OncoMed Pharmaceuticals
- 26 Feb 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017 as per ClinicalTrials.gov record.
- 26 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 05 Nov 2015 According to an OncoMed media release, the company de-prioritized and discontinued this trial to focus on solid tumor indications in biomarker selected populations.